Microcap Ledger Zenas BioPharma, Inc. $ZBIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 65,176,723 [10-Q 2026-08-13]
What the company doesAI summary of filing
Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology and inflammation-focused therapies. The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody in late-stage development for multiple autoimmune diseases, with positive Phase 3 results reported in January 2026 for immunoglobulin G4-related disease and positive Phase 2 data reported in October 2025 for relapsing multiple sclerosis. The company is pre-revenue, has generated no product sales to date, and is funding development through capital raises and a loan agreement. Zenas also develops orelabrutinib, a Bruton's Tyrosine Kinase inhibitor for progressive multiple sclerosis, and earlier-stage candidates including oral small molecule inhibitors in preclinical and IND-enabling stages. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.00M | −$192.44M | −$132.43M | $196.58M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $10.00M | −$377.74M | −$172.33M | $110.64M | [10-K 2026-03-16] |
| FY ended Dec 2024 | $5.00M | −$156.99M | −$119.67M | $319.74M | [10-K 2026-03-16] |
- Quarterly cash burn
- −$66.22M
- Cash runway Estimate
- ~8.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 41,791,037 | [10-Q 2024-11-12] |
| 2025-02-28 | 41,799,336 | [10-K 2025-03-11] |
| 2025-04-30 | 41,834,182 | [10-Q 2025-05-15] |
| 2025-07-31 | 42,110,313 | [10-Q 2025-08-12] |
| 2025-10-31 | 53,679,166 | [10-Q 2025-11-12] |
| 2026-02-28 | 57,361,260 | [10-K 2026-03-16] |
| 2026-04-30 | 63,133,377 | [10-Q 2026-05-13] |
| 2026-07-31 | 65,176,723 | [10-Q 2026-08-13] |
- Shelf registration
- S-3ASR filed 2026-09-11 [S-3ASR 2026-09-11]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-11 | S-3ASR | Registration statement |
| 2026-09-08 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-19 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-17 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations; Director or officer change |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations; Director or officer change; Shareholder vote results |
| 2026-05-05 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-04-02 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-03-31 | 8-K | Material agreement entered; New financial obligation; Other events |
Alerts for $ZBIO
Email me when Zenas BioPharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.